Image pharmaphorum Editor Views & Analysis How eligible patient numbers affect price of rare disease dr... Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for thes Views & Analysis Addressing leadership barriers for women in tech and pharma Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. Digital Deep Dive: Digital Health 2022 Following an unprecedented year of surging investment interest, the digital health industry is booming. Digital How a new investment is powering a revolution in clinical tr... Clinical trials are the engine for pharmaceutical innovation, but their means of capturing and communicating data are stuck in the past. Load more results
Views & Analysis How eligible patient numbers affect price of rare disease dr... Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for thes
Views & Analysis Addressing leadership barriers for women in tech and pharma Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry.
Digital Deep Dive: Digital Health 2022 Following an unprecedented year of surging investment interest, the digital health industry is booming.
Digital How a new investment is powering a revolution in clinical tr... Clinical trials are the engine for pharmaceutical innovation, but their means of capturing and communicating data are stuck in the past.
News AZ claims another win for Imfinzi in frontline liver cancer AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
